Jefferies reiterates Teva stock rating on pipeline potential

📌 Key Takeaways

• Jefferies maintains its stock rating for Teva Pharmaceutical Industries.
• The reaffirmation is based on the potential of Teva's drug pipeline.
• Analysts see promising future developments in Teva's upcoming products.
• The rating suggests confidence in Teva's long-term growth prospects.

🏷️ Themes

Pharmaceuticals, Investment Analysis

Entity Intersection Graph

No entity connections available yet for this article.

Source

investing.com